| Name | Title | Contact Details |
|---|
At Allegro MicroSystems, we`re passionate about developing intelligent solutions that move the world toward a safer and more sustainable future – while giving our customers a competitive edge. With more than 50 years of experience developing advanced semiconductor technology and application-specific algorithms, Allegro is a global leader in power and sensing solutions for motion control and energy-efficient systems. Through our innovations, we are helping our customers make breakthrough advancements in areas like advanced mobility, green energy, and factory automation. Each year, we ship over one billion units into these applications to support our 10,000+ customers around the globe, including over 50 automotive OEMs. Our diverse team of 3,500+ employees is spread across 13 countries, powering our global engineering, manufacturing, and support and enabling our innovations. That`s why we work hard to create a collaborative, energetic environment that rewards ingenuity and helps our employees make a difference every day.
Sentry Safety Supply is a Peoria, IL-based company in the Computers and Electronics sector.
Nor-Cal Products is a Yreka, CA-based company in the Computers and Electronics sector.
Epson enables people worldwide to make, share and capture creativity and bring it to life. Epson technologies open the door to limitless opportunities in visual communications, robotics, sensing, and business and commercial digital imaging. As a global innovator Epson applies its cutting-edge technologies in markets including sports, fashion, augmented reality, and personal healthcare.
Xceleron believes that AMS technology and our expertise can get life-changing products (drugs and biobased) quickly and cost-effectively to people who need them. We work with integrity and an open mind and are driven by science and the spirit of collaboration. Founded in 1997 in York, UK, and now headquartered in Germantown, Maryland, Xceleron pioneered human microdose and microtracer techniques using AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I, and Phase II/III clinical trials. Xceleron’s experience is especially valuable because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development.